August 21, 2024 06:45 AM EDT
Financing
Startups

Af­ter Pfiz­er lay­offs, Ar­ray chemists re­gath­er at next-gen obe­si­ty biotech Am­brosia Bio­sciences

Kyle LaHucik

Senior Reporter

A small piece of the multi­bil­lion-dol­lar re­struc­tur­ing at Pfiz­er has a light at the end of the tun­nel, and it’s in Boul­der, CO.

Just a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Mod­er­na plans $1.1B in R&D and pro­gram cuts, de­lays break-even point to 2028

Sanofi buys in­to ra­dio­phar­ma­ceu­ti­cal field with $110M up­front, go­ing af­ter space held by No­var­tis

A new start­up wants to fight can­cer with 'off-the-shelf' gene ther­a­py, se­cur­ing $26M seed round

Sofinno­va’s Jim Healy on ‘more ra­tio­nal mar­ket’ as four biotech star­tups near their IPOs

J&J ex­pands Trem­fya in­to IBD with new FDA ap­proval

Au­ra's in­frared light-ac­ti­vat­ed drug stops tu­mor growth and pre­serves vi­sion in eight eye can­cer pa­tients

A service from the Financial Times